{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:34:30Z","timestamp":1774629270313,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This study was supported in part by the Ruijin Hospital North Research Initiative Project","award":["2019ZX01"],"award-info":[{"award-number":["2019ZX01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr Metab (Lond)"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Although metabolic associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide, the exact molecular mechanism of MAFLD progression remains unknown. In the present study, Tandem Mass Tag-labeled quantitative proteomic technology was used to elucidate the protein expression patterns of liver tissues in the progression of MAFLD, providing new potential therapeutic targets of it.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Five 6-week-old male C57BL\/6 mice were fed with high fat diet (HFD) for 22\u00a0weeks to establish the MAFLD mouse models. Five C57BL\/6 mice of the same age were fed with normal diet (ND) and taken as controls. Mice serum were sampled for biochemical tests, and livers were isolated for histopathological examinations. Six mouse liver samples (three from each group) were performed for proteomic analysis. Differentially expressed proteins were defined using fold change of &gt;\u20091.5 or &lt;\u20090.67 and <jats:italic>p<\/jats:italic> value &lt;\u20090.05 as thresholds. Bioinformatic analysis was used to identify the hub proteins. Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR), Gene Expression Omnibus dataset, western blotting and immunohistochemistry were used to validate the expression of identified hub proteins.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>After 22\u00a0weeks on HFD diet, all mice developed MAFLD demonstrated by histopathological examination. Mouse body weights, liver weights, serum alanine transaminase and aspartate transaminase levels were significantly higher in the HFD group than ND group. Proteomics technology identified 4915 proteins in the mouse livers, among which 71 proteins were differentially expressed. Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that majority of the differentially expressed proteins were involved in the peroxisome and peroxisome proliferator-activated receptor signaling pathway, as well as biosynthesis of unsaturated fatty acids. Protein\u2013protein interaction analysis showed that these differentially expressed proteins interacted with each other and formed a complex network. Ten hub proteins were identified and validated using RT-qPCR. Five of these proteins were validated in the Gene Expression Omnibus dataset. Finally, Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase protein was validated in mouse liver tissue samples using western blotting and immunohistochemistry.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our data showed that lipid metabolism-related pathways are closely associated with the development of MAFLD. The identified hub proteins might be novel targets for treating MAFLD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12986-020-00522-3","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T06:03:32Z","timestamp":1605679412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tandem Mass Tag-based quantitative proteomics analysis of metabolic associated fatty liver disease induced by high fat diet in mice"],"prefix":"10.1186","volume":"17","author":[{"given":"Hu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peizhan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-6425","authenticated-orcid":false,"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014.","journal-title":"Gastroenterology"},{"key":"522_CR2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"522_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"522_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333.","journal-title":"Hepatology"},{"key":"522_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Minhui Paik J, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793\u2013801.","journal-title":"J Hepatol"},{"key":"522_CR6","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263\u201373.","journal-title":"JAMA"},{"key":"522_CR7","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672\u201382.","journal-title":"Hepatology"},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","volume":"7","author":"JS Lim","year":"2010","unstructured":"Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7:251\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"522_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"522_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s11427-017-9175-2","volume":"60","author":"X Li","year":"2017","unstructured":"Li X, Wang W, Chen J. Recent progress in mass spectrometry proteomics for biomedical research. Sci China Life Sci. 2017;60:1093\u2013113.","journal-title":"Sci China Life Sci"},{"key":"522_CR12","doi-asserted-by":"publisher","first-page":"eaa13321","DOI":"10.1126\/science.aal3321","volume":"356","author":"PJ Thul","year":"2017","unstructured":"Thul PJ, \u00c5kesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, et al. A subcellular map of the human proteome. Science. 2017;356:eaa13321.","journal-title":"Science"},{"key":"522_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fphar.2017.00099","volume":"8","author":"F Xia","year":"2017","unstructured":"Xia F, Yao X, Tang W, Xiao C, Yang M, Zhou B. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic analysis of Hugan Qingzhi and its protective properties against free fatty acid-Induced L02 hepatocyte injury. Front Pharmacol. 2017;8:99.","journal-title":"Front Pharmacol"},{"key":"522_CR14","doi-asserted-by":"publisher","first-page":"103683","DOI":"10.1016\/j.jprot.2020.103683","volume":"221","author":"X Yuan","year":"2020","unstructured":"Yuan X, Sun Y, Cheng Q, Hu K, Ye J, Zhao Y, et al. Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease. J Proteom. 2020;221:103683.","journal-title":"J Proteom"},{"key":"522_CR15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/nprot.2013.055","volume":"8","author":"A Mehlem","year":"2013","unstructured":"Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc. 2013;8:1149\u201354.","journal-title":"Nat Protoc"},{"key":"522_CR17","doi-asserted-by":"publisher","first-page":"e12836","DOI":"10.1111\/cpr.12836","volume":"53","author":"W Huang","year":"2020","unstructured":"Huang W, Yu D, Wang M, Han Y, Lin J, Wei D, et al. ITGBL1 promotes cell migration and invasion through stimulating the TGF-\u03b2 signalling pathway in hepatocellular carcinoma. Cell Prolif. 2020;53:e12836.","journal-title":"Cell Prolif"},{"key":"522_CR18","doi-asserted-by":"publisher","first-page":"W585","DOI":"10.1093\/nar\/gkm259","volume":"35","author":"P Horton","year":"2007","unstructured":"Horton P, Park KJ, Obayashi T, Fujita N, Harada H, Adams-Collier CJ, et al. WoLF PSORT: protein localization predictor. Nucleic Acids Res. 2007;35:W585-587.","journal-title":"Nucleic Acids Res"},{"key":"522_CR19","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"D Szklarczyk","year":"2015","unstructured":"Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447-452.","journal-title":"Nucleic Acids Res"},{"key":"522_CR20","doi-asserted-by":"publisher","first-page":"W438","DOI":"10.1093\/nar\/gkn257","volume":"36","author":"CY Lin","year":"2008","unstructured":"Lin CY, Chin CH, Wu HH, Chen SH, Ho CW, Ko MT. Hubba: hub objects analyser\u2014a framework of interactome hubs identification for network biology. Nucleic Acids Res. 2008;36:W438-443.","journal-title":"Nucleic Acids Res"},{"key":"522_CR21","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557\u201366.","journal-title":"Nat Med"},{"key":"522_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"B Gross","year":"2017","unstructured":"Gross B, Pawlak M, Lefebvre P, Staels B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol. 2017;13:36\u201349.","journal-title":"Nat Rev Endocrinol"},{"key":"522_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675\u201385.","journal-title":"N Engl J Med"},{"key":"522_CR25","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","volume":"10","author":"Y Sasaki","year":"2020","unstructured":"Sasaki Y, Asahiyama M, Tanaka T, Yamamoto S, Murakami K, Kamiya W, et al. Pemafibrate, a selective PPARalpha modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci Rep. 2020;10:7818.","journal-title":"Sci Rep"},{"key":"522_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","volume":"63","author":"S Francque","year":"2015","unstructured":"Francque S, Verrijken A, Caron S, Prawitt J, Paumelle R, Derudas B, et al. PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol. 2015;63:164\u201373.","journal-title":"J Hepatol"},{"key":"522_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1194\/jlr.M024463","volume":"53","author":"SM Houten","year":"2012","unstructured":"Houten SM, Denis S, Argmann CA, Jia Y, Ferdinandusse S, Reddy JK, et al. Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. J Lipid Res. 2012;53:1296\u2013303.","journal-title":"J Lipid Res"},{"key":"522_CR28","doi-asserted-by":"publisher","first-page":"e16542","DOI":"10.1371\/journal.pone.0016542","volume":"6","author":"K Banasik","year":"2011","unstructured":"Banasik K, Justesen JM, Hornbak M, Krarup NT, Gjesing AP, Sandholt CH, et al. Bioinformatics-driven identification and examination of candidate genes for non-alcoholic fatty liver disease. PLoS ONE. 2011;6:e16542.","journal-title":"PLoS ONE"},{"key":"522_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.devcel.2008.10.015","volume":"15","author":"DT Rutkowski","year":"2008","unstructured":"Rutkowski DT, Wu J, Back SH, Callaghan MU, Ferris SP, Iqbal J, et al. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev Cell. 2008;15:829\u201340.","journal-title":"Dev Cell"},{"key":"522_CR30","first-page":"6708061","volume":"2020","author":"X Tian","year":"2020","unstructured":"Tian X, Ru Q, Xiong Q, Wen R, Chen Y. Catalpol attenuates hepatic steatosis by regulating lipid metabolism via AMP-activated protein kinase activation. Biomed Res Int. 2020;2020:6708061.","journal-title":"Biomed Res Int"},{"key":"522_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jep.2014.04.011","volume":"154","author":"J Yin","year":"2014","unstructured":"Yin J, Luo Y, Deng H, Qin S, Tang W, Zeng L, et al. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARalpha pathways in L02 cells and HepG2 cells. J Ethnopharmacol. 2014;154:229\u201339.","journal-title":"J Ethnopharmacol"}],"container-title":["Nutrition &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-020-00522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12986-020-00522-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-020-00522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T06:13:20Z","timestamp":1605680000000},"score":1,"resource":{"primary":{"URL":"https:\/\/nutritionandmetabolism.biomedcentral.com\/articles\/10.1186\/s12986-020-00522-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1186\/s12986-020-00522-3","relation":{},"ISSN":["1743-7075"],"issn-type":[{"value":"1743-7075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were performed with approval from the Institutional Animal Care and Use Committee of Ruijin Hospital, Shanghai Jiaotong University School of Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}